Baxter International has recalled one lot each of 70% Dextrose Injection and Anticoagulant Sodium Citrate Solution due to the potential presence of particulate matter.
The 70% Dextrose Injection may contain stainless steel particles, according to an Aug. 25 FDA alert. The affected product is lot Y495066, which expires July 31, 2027. It was distributed July 25-28, 2026, to healthcare providers and distributors in select states, including Alabama, Georgia and Tennessee.
Baxter also recalled lot Y493475 of Anticoagulant Sodium Citrate Solution due to the potential presence of fiberglass. The product, which expires Dec. 31, 2027, was distributed July 2-11, 2026, to one customer in the U.S.
Stainless steel particles in the dextrose injection may cause blood vessel blockage and clotting, pulmonary embolism, permanent organ damage or death. Particles in the anticoagulant solution may cause vein irritation, inflammatory or hypersensitivity reactions and systemic embolization that could lead to tissue or organ injury.
In a statement shared with Becker’s, Baxter said it maintains “rigorous quality and testing processes aligned to current regulatory requirements” and continues to invest in enhanced detection and monitoring capabilities. As of Sept. 1, the company said it has not received any reports of adverse events associated with the recalled lots and remains in contact with the FDA.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
